In order to ensure an adequate and safe blood supply, the plateletpheresis donor deferral rate in family replacement donors and volunteer donors were analyzed in this study. The study was undertaken in Chongqing Blood Center, China. Nucleic acid testing (NAT) and ELISA were applied to assess the hepatitis B virus surface antigen (HBsAg), antibodies against hepatitis C virus (anti-HCV), human immunodeficiency virus (HIV) and Treponema palladium（TP）in plateletpheresis donors. From January 2015 to December 2016, a total of 17,342 plateletpheresis donors in Chongqing blood center were enrolled in this study. Among the 3,642 plateletpheresis donors, 21.00% were younger than 25, followed by 26–35 years group (41.19%), 36-45 years group (22.46%), 46-55 years group (13.97%) and 56-60 years group (1.38%). Replacement and voluntary donors contributed 5,305 (30.59%) and 12,037 (69.41%), respectively. Among all the plateletpheresis donors, 194 (1.12%) were deferred because of seropositive serology. Replacement and voluntary deferred donors comprised 109 (2.05%) and 85 (0.68%), respectively (P<0.05). Among the deferred donors, 194 (1.12%) were seropositive for HBsAg (0.44%), followed by anti-HCV (0.28%), TP (0.24%) and HIV (0.15%). Prevalence deferred females contributed 67 (1.60%), while males contributed 127 (0.97%) of the deferred cases, respectively (P<0.05). Deferral rate was highest among 46-55 years group (1.65%) followed by 36-45 years group (1.63%), The other groups were less than 1%. It is necessary to reduce family replacement donors and replace them with regular volunteer donors, and to improve blood donor retention strategies to boost the regular blood donors’ motivating. In addition to increasing and maintaining volunteer supply, it is desirable to keep the deferral rate at a low level, to ensure an adequate and safe blood supply.